CancerVax | Jotup

CancerVax Launches $5 Million Funding Round

Retrieved on:

Wednesday, April 3, 2024

CancerVax, Research, UCLA, Regulation, Cancer, Online shopping

Lehi, Utah, April 03, 2024 (GLOBE NEWSWIRE) -- CancerVax, Inc., developer of a breakthrough Universal Cancer Vaccine treatment that will use the body’s immune system to fight cancer, today announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million.

Key Points:

Lehi, Utah, April 03, 2024 (GLOBE NEWSWIRE) -- CancerVax, Inc., developer of a breakthrough Universal Cancer Vaccine treatment that will use the body’s immune system to fight cancer, today announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million.
Proceeds from the SEC qualified Reg A+ offering will be used by the Company to continue work on its breakthrough cancer treatments.
CancerVax CEO, Byron Elton said, “We are very excited about the Company’s progress to date.
Thus far, we’ve raised $3.3 million of seed funding and plan to raise an additional $5 million to further the development of our novel cancer treatments.”
The offering is available to the general public.

CancerVAX CEO Ryan Davies Discusses Cancer Drug Development with Dr. Ezra Cohen

Retrieved on:

Thursday, November 2, 2023

Attention, Moores Cancer Center, CancerVax, San Diego, University, Medicine, University of Chicago, Cancer, Patient, Associate, Pharmaceutical industry, LEHI

LEHI, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago.

Key Points:

LEHI, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago.
“I got into medicine to make a difference in people’s lives, said Dr. Cohen.
“I realized that cancer patients needed more focus and more attention than other patient groups.
Cohen is a lovely man with incredible experience and noble intentions,” said CancerVax CEO, Ryan Davies.

OncoResponse Announces Appointment of Carol Gallagher to Board of Directors

Retrieved on:

Wednesday, September 6, 2023

Gilead Sciences, Amgen, Drug development, Pharming, Mirati Therapeutics, Cancer, CancerVax, Immunotherapy, Eli Lilly, NEA, Biogen, Immune system, New Enterprise Associates, Pharmaceutical industry, Trustee, Pfizer

SEATTLE, Sept. 6, 2023 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced the appointment of Carol Gallagher, Pharm.D., as an Independent Director to its Board of Directors.

Key Points:

SEATTLE, Sept. 6, 2023 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced the appointment of Carol Gallagher, Pharm.D., as an Independent Director to its Board of Directors.
Dr. Gallagher is an experienced board director and operator who brings over 30 years' experience in drug development, business development, and commercial activities.
From 2008 to 2011, Dr. Gallagher served as President and CEO of Calistoga, which was acquired by Gilead Sciences.
"I'm thrilled to join the Board at OncoResponse and look forward to working with the team to achieve new breakthroughs in immunotherapy," said Dr. Gallagher.

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Retrieved on:

Monday, July 10, 2023

Heart, Learning, IPO, University, Wharton School of the University of Pennsylvania, CancerVax, Intelligence, Research, Drug development, Therapy, Cornell University, Pharmaceutical industry, LEHI, Cancer, Pfizer

LEHI, Utah, July 10, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Pyxis Oncology President & CEO, Dr. Lara Sullivan, discussed her journey as a biotech entrepreneur and executive at Pfizer.

Key Points:

LEHI, Utah, July 10, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Pyxis Oncology President & CEO, Dr. Lara Sullivan, discussed her journey as a biotech entrepreneur and executive at Pfizer.
“They were reinventing their R&D approach with more efficient processes, while also placing a greater emphasis on innovation.
Drug development is an apprenticeship model just like medicine.”
“We gained a number of insights from this discussion that can be applied to our own research,” said CancerVax CEO, Ryan Davies.
Prior to joining Pyxis Oncology, Dr. Sullivan was Founding President of SpringWorks Therapeutics, a clinical stage biopharmaceutical company she conceived of, founded, and spun out from Pfizer.

Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director

Retrieved on:

Friday, June 23, 2023

SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.

Key Points:

SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.
Dr. Gallagher has over 30 years of strategic, commercial, business development and drug development leadership experience in the life sciences industry.
A veteran board director, Dr. Gallagher currently serves as a board member of PMV Pharma, Atara Biotherapeutics and, until its recent acquisition by Bristol Myers Squibb in August 2022, Turning Point Therapeutics.
Dr. Gallagher commented, "I am thrilled to join the Mirati Therapeutics board of directors during this transformational time for the company.

Biotech Executive Michael Smith Discusses the FDA Drug Development Process with CancerVAX CEO Ryan Davies

Retrieved on:

Friday, June 16, 2023

Biotechnology, BS, Drug development, Doctor of Pharmacy, University, Senior, Cancer, CancerVax, Immunotherapy, Development, PRA Health Sciences, Knowledge, Growth, FDA, BYU, Pharmaceutical industry, Pharmacy, Neuroscience, LEHI

LEHI, Utah, June 16, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that its CEO, Ryan Davies and biotech executive Michael Smith recently discussed the FDA drug development process and the growth of immunotherapy treatments.

Key Points:

LEHI, Utah, June 16, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that its CEO, Ryan Davies and biotech executive Michael Smith recently discussed the FDA drug development process and the growth of immunotherapy treatments.
“Immunotherapy, of course, has made a tremendous leap and I think that it will continue to do so,” said Mr. Smith.
“It was insightful and delightful speaking with Mike,” said CancerVax CEO, Ryan Davies.
It’s been fun to watch him ascend into meaningful roles in the biotech space.”
For more information about CancerVAX, please visit http://www.cancervax.com .

CancerVAX Launches $10 Million Funding Round

Retrieved on:

Wednesday, June 14, 2023

Cancer, CancerVax, UCLA, Risk, Online shopping, LEHI

LEHI, Utah, June 14, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that it recently launched a funding round of up to $10 million.

Key Points:

LEHI, Utah, June 14, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that it recently launched a funding round of up to $10 million.
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments.
CancerVax CEO, Ryan Davies said, “We’re working with a research team at UCLA to help us develop these treatments.
For more information about the offering, please visit http://startengine.com/cancervax
For more information about CancerVax, please visit http://www.cancervax.com/ .

CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

Retrieved on:

Monday, June 12, 2023

Monoclonal antibody, Radiation, Ryan Davies, Cancer, CancerVax, Immunotherapy, Research, CAR, Patient, Physician, Immune system, Ewing sarcoma, UCLA, Vaccine, LEHI

LEHI, Utah, June 12, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that its UCLA research team has made positive progress towards developing a treatment for Ewing sarcoma, a deadly form of kids cancer.

Key Points:

LEHI, Utah, June 12, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that its UCLA research team has made positive progress towards developing a treatment for Ewing sarcoma, a deadly form of kids cancer.
Ewing sarcoma is an aggressive bone and soft-tissue cancer with limited chances of cure, more prevalent in adolescents and young adults.
CancerVax is working with a team of experienced cancer researchers and physicians at UCLA.
Immunotherapy, which uses the body’s own immune system, represents a new paradigm of cancer treatment that helps patients get better without feeling worse by being highly targeted.”
Ewing sarcoma is 1 of 2 major cancer research programs CancerVAX has with UCLA.

CancerVAX CEO Ryan Davies and Raymond Vennare Discuss the Cancer Fighting Role of Universities

Retrieved on:

Tuesday, June 6, 2023

Biotechnology, University, Cancer, FDA, CancerVax, Therapy, Pharmaceutical industry, LEHI

Raymond F. Vennare currently serves as CEO and Chairman of the Board of Predictive Oncology Inc., one of the nation's largest biobanks containing $ 400 million of tumor samples.

Key Points:

Raymond F. Vennare currently serves as CEO and Chairman of the Board of Predictive Oncology Inc., one of the nation's largest biobanks containing $ 400 million of tumor samples.
Mr. Vennare has more than thirty years of experience as an accomplished senior executive, board director and biotechnology entrepreneur.
Throughout his career, Mr. Vennare has played a key role in the capitalization, development and commercialization of innovative and novel technologies.
During their conversation, Mr. Davies and Mr. Vennare discussed the important role that universities play in the fight to treat cancer.

CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist

Retrieved on:

Wednesday, April 12, 2023

Certificate, Elgin Mental Health Center, Cancer, CancerVax, Medicine, Woodhull Medical Center, Haematopoietic system, History, Patient, Child, Pleasure, Biology, Hospital, UCLA, Society, Hematopoietic stem cell transplantation, Disease, Nursing, LEHI

LEHI, Utah, April 12, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, reported that CEO Ryan Davies spoke about the importance of cancer immunotherapy with Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA.

Key Points:

LEHI, Utah, April 12, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, reported that CEO Ryan Davies spoke about the importance of cancer immunotherapy with Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA.
He received his medical degree in Brazil and completed his pediatric residency at Woodhull Medical and Mental Health Center in New York and his pediatric hematology/oncology fellowship at the Children’s Hospital Lost Angeles.
His clinical focus is on pediatric oncology and gene therapies and his research focus is on cancer immunotherapy and biology of stem cell transplantation.
And now, this patient is a miracle,’ We’re really building the history of medicine.”
CancerVax CEO Ryan Davies commented, “It was a pleasure speaking with Dr. De Oliveira.